phthalidyl trans-4-aminomethylcyclohexanecarboxylate hydrochloride | 100165-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: phthalidyl trans-4-aminomethylcyclohexanecarboxylate hydrochloride
• CAS: 100165-52-4
• 化学式: C₁₆H₁₉NO₄*ClH
• 分子量: 325.792
• InChiKey: QJLIJWIGAOLOHD-RZXVNOQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.59
• 重原子数：
  22.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.62
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  tranexamic acid 在 盐酸 、 sodium hydroxide 、 四丁基硫酸氢铵 作用下， 以 水 、 乙酸乙酯 、 叔丁醇 为溶剂， 反应 24.0h， 生成 phthalidyl trans-4-aminomethylcyclohexanecarboxylate hydrochloride
  参考文献：
  名称：

  Tranexamic acid derivatives with enhanced absorption

  摘要：

  Derivatives of the antifibrinolytic drug tranexamic acid [trans-4-(aminomethyl)cyclohexanecarboxylic acid] containing one or two tranexamic acid moieties were synthesized. Most of the derivatives have good stability in acidic and neutral solutions but are easily hydrolyzed in plasma. By measuring the amount of tranexamic acid excreted in the urine after an oral dose, relative absorptions of a number of derivatives in the rat were estimated. Most of the derivatives showed greater absorption than tranexamic acid itself. 1-[(Ethoxycarbonyl)oxy]ethyl trans-4-(amino-methyl)cyclohexanecarboxylate hydrochloride was chosen for studies in man.

  DOI：

  10.1021/jm00154a004

文献信息

• Antifibrinolytically active derivatives of tranexamic acid
  申请人：KabiVitrum AB

  公开号：US04483867A1

  公开（公告）日：1984-11-20

  Novel antifibrinolytically active compounds of the formula ##STR1## and therapeutically acceptable salt thereof, wherein R.sup.1 is selected from the group consisting of (a) alkyl groups containing 1-4 carbon atoms, (b) alkoxy groups containing 1-4 carbon atoms, ##STR2## R.sup.2 is selected from the group consisting of (a) H, (b) alkyl groups containing 1-4 carbon atoms, (c) --COOR.sup.3, wherein R.sup.3 is an alkyl group containing 1-4 carbon atoms, (d) --CONR.sup.4 R.sup.5, wherein R.sup.4 and R.sup.5 are the same or different alkyl groups containing 1-3 carbon atoms; or wherein R.sup.1 and R.sup.2 represent together the radical ##STR3##

  化合物的新型抗纤溶活性化合物的结构式为##STR1##及其治疗上可接受的盐，其中R.sup.1选自以下组：(a)含有1-4个碳原子的烷基基团，(b)含有1-4个碳原子的烷氧基团，##STR2##R.sup.2选自以下组：(a)H，(b)含有1-4个碳原子的烷基基团，(c)--COOR.sup.3，其中R.sup.3是含有1-4个碳原子的烷基基团，(d)--CONR.sup.4 R.sup.5，其中R.sup.4和R.sup.5是相同或不同的含有1-3个碳原子的烷基基团；或其中R.sup.1和R.sup.2共同表示如下基团##STR3##
• Antifibrinolytically active compounds
  申请人：KabiVitrum AB

  公开号：EP0079872A1

  公开（公告）日：1983-05-25

  Novel antifibrinolytically active compounds of the formula and therapeutically acceptable salt thereof, wherein R1 is selected from the group consisting of (a) alkyl groups containing 1-4 carbon atoms, (b) alkoxy groups containing 1-4 carbon atoms, R2 is selected from the group consisting of (a) H, (b) alkyl groups containing 1-4 carbon atoms, (c) -COOR3, wherein R3 is an alkyl group containing 1-4 carbon atoms, (d) -CONR4R5, wherein R4 and R5 are the same or different alkyl groups containing 1-3 carbon atoms; or wherein R1 and R2 represent together the radical

  式中的新型抗纤维蛋白溶解活性化合物 及其治疗上可接受的盐，其中 R1 选自以下组成的组 (a) 含 1-4 个碳原子的烷基、 (b) 含 1-4 个碳原子的烷氧基、 R2 选自以下组别 (a) H (b) 含 1-4 个碳原子的烷基、 (c) -COOR3，其中 R3 是含 1-4 个碳原子的烷基、 (d) -CONR4R5，其中 R4 和 R5 是相同或不同的含 1-3 个碳原子的烷基；或 其中 R1 和 R2 共同代表基团
• US4483867A
  申请人：——

  公开号：US4483867A

  公开（公告）日：1984-11-20
• Tranexamic acid derivatives with enhanced absorption
  作者：Carl M. Svahn、Ferenc Merenyi、Lennart Karlson

  DOI：10.1021/jm00154a004

  日期：1986.4

  Derivatives of the antifibrinolytic drug tranexamic acid [trans-4-(aminomethyl)cyclohexanecarboxylic acid] containing one or two tranexamic acid moieties were synthesized. Most of the derivatives have good stability in acidic and neutral solutions but are easily hydrolyzed in plasma. By measuring the amount of tranexamic acid excreted in the urine after an oral dose, relative absorptions of a number of derivatives in the rat were estimated. Most of the derivatives showed greater absorption than tranexamic acid itself. 1-[(Ethoxycarbonyl)oxy]ethyl trans-4-(amino-methyl)cyclohexanecarboxylate hydrochloride was chosen for studies in man.